Data di Pubblicazione:
2011
Citazione:
Evaluation of clinical evidence for the use of HE4 in diagnosis of ovarian cancer (OC) / M. Lanzoni, S. Ferraro, P. Boracchi, E. Biganzoli. ((Intervento presentato al convegno Congresso nazionale della Societa’ Italiana di Biometria (SIB) tenutosi a Gargnano del Garda nel 2011.
Abstract:
Ovarian cancer(OC) is the sixth most common cancer in women and the first cause of death
between gynecologic malignancies. The 75% of OCs are diagnosed at an advanced stage and no
effective prevention is performed. Among the wide spectrum of genomic and immunohistochemical studies on OC biomarkers only Human Epididymis 4 (HE4) seems could
improve OC diagnosis if co-detected with CA125. However only few studies on diagnostic
accuracy are published and thus a review of available studies for this biomarker should be critical to assess its clinical validity and efficacy. According to available studies no reliable evidences emerged supporting the clinical introduction of this marker, and neither the single nor the parallel
marker detection improves the rule out for early and overall OCs.
Tipologia IRIS:
14 - Intervento a convegno non pubblicato
Keywords:
HE4 ; ovarian cancer ; diagnosis
Elenco autori:
M. Lanzoni, S. Ferraro, P. Boracchi, E. Biganzoli
Link alla scheda completa: